Lymphedema Treatment Market ShareTrends growth Share, Analysis, Global Industry Demand
Industry Report “Lymphedema Treatment Market Research Report — Global Forecast till 2025” provides a clear picture of the Current Market Scenario which includes past and estimated future size with respect to value and volume, technological advancement, macro economical and governing factors in the Lymphedema Treatment Market.
Lymphedema Treatment Market is estimated to grow with a CAGR of 4.0%.
Market Synopsis
The increasing prevalence of cancer is expected to drive the Global lymphedema treatment market by treatment.
The strong clinical pipeline is likely to boost the market growth. Market players like HERANTIS PHARMA PLC, are developing curative treatment of secondary lymphedema — Lymfactin. Lymfactin is the world’s first and only clinical-stage gene therapy against lymphedema. The market potential of the drug is estimated to be around USD 650 Million.
Market Influencer
Increased research & development in the market is estimated to influence the commercialization in the market. The market is projected to witness a shift from symptomatic treatments to targeted treatment during the forecast period of 2018 to 2025.
Key Players
- 3A Health Care (Italy)
- Bio Compression Systems, Inc. (US)
- Devon Medical Products (US)
- HERANTIS PHARMA PLC (Finland)
- Lohmann & Rauscher (Germany)
- Mego Afek Ltd (US)
- SIGVARIS (Switzerland)
- Tactile Systems Technology Inc. (US)
- Wright Therapy Products (BSN Medical) (Germany)
Segmentation
By Type
- Primary Lymphedema is caused by the abnormal development of the lymph system. Symptoms may occur at birth or older age. The primary lymphedema segment is estimated to hold the least market share in 2018.
- Secondary Lymphedema is caused by damage to the lymph system owing to cancer treatment involving surgery, radiation therapy, and others. A majority of the patients suffered from secondary lymphedema making this the leading segment in 2018.
By Affected Area
- Lower Extremity: Lower extremity lymphedema involves the swelling of ankles, legs, and feet. This segment is estimated to hold a share of 0% in 2018.
- Upper Extremity: Upper extremity lymphedema is one of the most poorly understood complications of the disease, making the segment to hold a share of 9.0% in the market in 2018.
- Genitalia: This segment held the least share of the market in 2018.
GET FULL REPORT @ https://www.marketresearchfuture.com/reports/lymphedema-treatment-market-8440
Market Influencer
Increased research & development in the market is estimated to influence the commercialization in the market. The market is projected to witness a shift from symptomatic treatments to targeted treatment during the forecast period of 2018 to 2025.
Related News
